利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Treatment using dantrolene
    2.
    发明授权
    Treatment using dantrolene 有权
    使用丹曲林治疗

    公开(公告)号：US08685460B2

    公开(公告)日：2014-04-01

    申请号：US13353478

    申请日：2012-01-19

    申请人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    IPC分类号： A61K9/16 ,  A61K31/415 ,  A61K9/00 ,  A61K9/10 ,  A61K31/4166 ,  C07D233/80

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

    TREATMENT USING DANTROLENE
    3.
    发明申请
    TREATMENT USING DANTROLENE 有权
    使用DANTROLENE治疗

    公开(公告)号：US20120121663A1

    公开(公告)日：2012-05-17

    申请号：US13353480

    申请日：2012-01-19

    申请人： David Anderson ,  Benjamin G. Cameransi, JR. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, JR. ,  Vincent M. Conklin

    IPC分类号： A61K31/4178 ,  A61K9/10 ,  A61P43/00

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

    TREATMENT USING DANTROLENE
    4.
    发明申请
    TREATMENT USING DANTROLENE 有权
    使用DANTROLENE治疗

    公开(公告)号：US20100160400A1

    公开(公告)日：2010-06-24

    申请号：US12717588

    申请日：2010-03-04

    申请人： David Anderson ,  Benjamin G. Cameransi, JR. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, JR. ,  Vincent M. Conklin

    IPC分类号： A61K31/4178 ,  A61P23/00 ,  A61P9/00 ,  A61P21/02 ,  A61P25/28

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

    Treatment using dantrolene
    5.
    发明授权
    Treatment using dantrolene 有权
    使用丹曲林治疗

    公开(公告)号：US08604072B2

    公开(公告)日：2013-12-10

    申请号：US13353480

    申请日：2012-01-19

    申请人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    IPC分类号： A61K31/415 ,  A61K9/14 ,  A61K9/00

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

    Treatment using dantrolene
    7.
    发明授权
    Treatment using dantrolene 有权
    使用丹曲林治疗

    公开(公告)号：US08110225B2

    公开(公告)日：2012-02-07

    申请号：US12717588

    申请日：2010-03-04

    申请人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    IPC分类号： A61K9/14 ,  A61K9/00 ,  A61K31/415

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

    Treatment using dantrolene
    9.
    发明授权
    Treatment using dantrolene 有权
    使用丹曲林治疗

    公开(公告)号：US07758890B2

    公开(公告)日：2010-07-20

    申请号：US10788413

    申请日：2004-03-01

    申请人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    发明人： David Anderson ,  Benjamin G. Cameransi, Jr. ,  Vincent M. Conklin

    IPC分类号： A61K9/14 ,  A61K9/00 ,  A61K31/415

    CPC分类号： A61K31/4178 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1274 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/18 ,  C07D233/80

    摘要： Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

    摘要翻译： 低剂量安非他酮注射剂配方，与目前批准和上市的丹曲林相比，具有威胁麻醉危险的MH。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 另外，可以广泛使用非麻醉医师从事静脉内使用丹曲罗治疗其他潜在危及生命的疾病，包括在现场的非麻醉医师。 对于预防和治疗泵头以及其他神经系统，认知和运动功能障碍，医源性或创伤性诱发的情况，丹那罗林的低体积，安全注射剂型以及其他丹曲林制剂具有显着优点。 改变的血液流量，包括涉及CPB或相关手术的手术过程中发生的血流量以及在医源性或疾病引起的非正常体温发作期间发生的血流量。